A61K 31/541
Non-condensed thiazines containing further heterocyclic rings
A61K31/541 (Non-condensed thiazines containing further heterocyclic rings) appears on 987 US grants and 1,672 published applications in this corpus.
Search patents in A61K- Granted patents
- 987
- Published applications
- 1,672
- Assignees
- 612
- Inventors
- 4,651
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 3 | 0 |
| 1998 | 1 | 0 |
| 1999 | 7 | 0 |
| 2000 | 7 | 0 |
| 2001 | 8 | 1 |
| 2002 | 6 | 29 |
| 2003 | 10 | 48 |
| 2004 | 22 | 33 |
| 2005 | 18 | 48 |
| 2006 | 19 | 34 |
| 2007 | 11 | 37 |
| 2008 | 26 | 26 |
| 2009 | 16 | 29 |
| 2010 | 15 | 39 |
| 2011 | 14 | 42 |
| 2012 | 31 | 46 |
| 2013 | 49 | 97 |
| 2014 | 55 | 82 |
| 2015 | 80 | 125 |
| 2016 | 83 | 123 |
| 2017 | 105 | 112 |
| 2018 | 72 | 81 |
| 2019 | 82 | 68 |
| 2020 | 48 | 65 |
| 2021 | 45 | 55 |
| 2022 | 24 | 55 |
| 2023 | 25 | 56 |
| 2024 | 36 | 127 |
| 2025 | 35 | 98 |
| 2026 | 34 | 116 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Sirt6 activators6 Oct 2026US 12,753,180 B2Board of Regents, The University of Texas System
- LOX enzyme inhibiting methods and compositions29 Sep 2026US 12,746,243 B2Anovia Biosciences, Inc.
- Inhibitors and uses thereof22 Sep 2026US 12,740,991 B2Vividion Therapeutics, Inc.
- Quinoxaline derivatives and uses thereof22 Sep 2026US 12,741,976 B2Black Diamond Therapeutics, Inc.
- MALT-1 modulators8 Sep 2026US 12,729,201 B2Recursion Pharmaceuticals, Inc.
- Cell proliferation modulators and uses thereof1 Oct 2026US 2026/0294925 A1Kumquat Biosciences Inc.
- Sulfoximine compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same1 Oct 2026US 2026/0297073 A1Chong Kun Dang Pharmaceutical Corp.
- Sulfoximine compound having FGFR inhibitory effect, pharmaceutical composition comprising same, and use thereof1 Oct 2026US 2026/0297093 A1Kinoteck Therapeutics Co., Ltd.
- Hdac1/2 selective inhibitor and use thereof1 Oct 2026US 2026/0297110 A1Wigen Biomedicine Technology (Shanghai) Co., Ltd.
- Parg inhibitory compounds24 Sep 2026US 2026/0284069 A1Forx Therapeutics AG
Most cited
By later US patents
- 2,4-disubstituted pyrimidines useful as kinase inhibitors178US 8,338,439 B2Celgene Avilomics Research, Inc. · 2012
- Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds176US 7,122,542 B2Rigel Pharmaceuticals, Inc. · 2006
- Pyrimidine derivatives109US 6,200,977 B1Tularik Inc. · 2001
- Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds106US 7,582,648 B2Rigel Pharmaceuticals, Inc. · 2009
- Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds104US 7,452,879 B2Rigel Pharmaceuticals, Inc. · 2008